Japan Tobacco, Inc.

11 articles about Japan Tobacco, Inc.

• Akebia Therapeutics Announces Collaboration Partner’s Positive Top-line Results of Phase 3 Clinical Study of Riona® (ferric citrate hydrate) in Adult Patients with Iron Deficiency Anemia in Japan

  7/10/2019

  Upon successful completion of its Phase 3 program, JT and Torii stated that they expect to file an application for approval of IDA as an additional indication for Riona in Japan.

• Opko Health Inks $118 Million Deal with Japan Tobacco, Inc. for Rayaldee

  10/12/2017

• Keryx Biopharmaceuticals Announces Positive Top-Line Results from Phase 3 Study of Ferric Citrate (Zerenex™) in Japan by Partner, Japan Tobacco, Inc. and Torii Pharmaceutical Co.

  4/23/2012

• Merck & Co., Inc. Ditches Bone Drug Deal with Japan Tobacco, Inc.

  10/17/2011

• Keryx Biopharmaceuticals Announces Commencement of Phase 3 Program of Ferric Citrate (Zerenex(TM)) in Japan by Partner, Japan Tobacco, Inc. and Torii Pharmaceutical Co.

  4/18/2011

• Japan Tobacco's Novel Osteoporosis Drug Promising in Early Study

  9/17/2009

• Orphagen Pharmaceuticals Announces Collaboration And License Agreement With Japan Tobacco

  1/7/2009

• Merck & Co., Inc. (JOBS), Japan Tobacco in Osteoporosis Drug Deal

  9/25/2008

• Keryx Biopharmaceuticals Licenses Rights to Japan Tobacco; Torii Pharmaceutical Co. to Pay up to $100 Million

  9/26/2007

• Arcadia Biosciences, Inc. Licenses Corn And Rice Transformation Technology From Japan Tobacco

  10/2/2006

• Japan Tobacco And GlaxoSmithKline Conclude Licensing Agreement For New Drug Candidate

  4/20/2006